MDxHealth NV (OTCMKTS:MXDHF) is a molecular diagnostics company specializing in innovative tests designed to improve cancer detection, prognosis and treatment decisions. Founded in 2005 and headquartered in Roeselare, Belgium, the company leverages proprietary nuclear RNA‐based technologies to develop noninvasive assays that guide clinicians in stratifying patient risk and optimizing care pathways. MDxHealth’s suite of products addresses major oncology areas with a focus on prostate, bladder and colorectal cancers.
The company’s flagship prostate cancer portfolio includes SelectMDx, a urine-based assay that helps determine the likelihood of high-grade prostate cancer, and ConfirmMDx, a tissue-based epigenetic test designed to detect “missed” cancers in patients with previous negative biopsy results. In bladder cancer, MDxHealth has developed the Bladder EpiCheck test, which provides a noninvasive method to monitor recurrence by analyzing epigenetic markers in urine samples. The colorectal cancer pipeline features PrecisionPath, an RNA-based test for distinguishing high-risk lesions during routine colonoscopy screenings.
MDxHealth maintains a global footprint with commercial operations across the United States, Europe and select markets in Asia. Regulatory clearances from both the U.S. Food and Drug Administration (FDA) and leading European authorities support the clinical adoption of its assays. The company collaborates with academic institutions, hospitals and contract research organizations to validate its tests in real-world settings, ensuring that the data generated aligns with evolving guidelines in precision oncology.
Under the leadership of CEO Jos Koeckhoven, Ph.D., MDxHealth has pursued strategic growth through partnerships and targeted product launches. The executive team combines expertise in molecular biology, clinical development and commercial strategy, with a board of directors that includes seasoned healthcare investors and scientific advisors. This management structure aims to drive the company’s mission of delivering actionable insights for clinicians and improving outcomes for cancer patients worldwide.
AI Generated. May Contain Errors.
Free MXDHF Stock Alerts